DMAA Drugs Made In America Acquisition Corp.: institutional ownership and insider trading
26 funds reported holding $136M of Drugs Made In America Acquisition Corp. in their latest 13F filings; in Q2 2026 funds net sold $117M, with 1 new positions and 17 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Largest institutional holders of DMAA
- Karpus Management, Inc. — $26.7M
- MIZUHO SECURITIES USA LLC — $20.9M
- Polar Asset Management Partners Inc. — $12.2M
- GLAZER CAPITAL, LLC — $10.6M
- WOLVERINE ASSET MANAGEMENT LLC — $8.86M
- HIGHBRIDGE CAPITAL MANAGEMENT LLC — $8.62M
- First Trust Capital Management L.P. — $8.38M
- HEIGHTS CAPITAL MANAGEMENT, INC — $6.90M
- Westchester Capital Management, LLC — $6.20M
- MIZUHO SECURITIES USA LLC — $5.40M
Recent DMAA insider trades
- Feb 18, 2025: Stockwell Lynn bought 30,000 shares ($0)
- Feb 18, 2025: Drugs Made In America Acquisition LLC bought 30,000 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC sold 5,698,363 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC bought 400,000 shares ($0)
5%+ owners
- KARPUS MANAGEMENT, INC.: 10.3% (Schedule 13G/A, filed Aug 14, 2026)
- Mizuho Financial Group, Inc.: 8.5% (Schedule 13G/A, filed Aug 13, 2026)
- Feis Equities LLC: 5.1% (Schedule 13G, filed Jun 26, 2026)